RET and non-small cell lung carcinoma: The RET-MAP multicenter retrospective study enrolled 218 patients with RET fusion-positive NSCLC who received, alternatively, monotherapy, doublet chemotherapy, immune checkpoint inhibitors (ICIs), chemotherapy combined with ICIs, mTKIs, and RETi.